Holen Sie sich die Stockscreener-App
84.53
0.58%
-0.5813
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$85.11
Offen:
$84.65
24-Stunden-Volumen:
299.39K
Relative Volume:
0.15
Marktkapitalisierung:
$11.94B
Einnahmen:
$622.01M
Nettoeinkommen (Verlust:
$-271.86M
KGV:
-39.34
EPS:
-2.1484
Netto-Cashflow:
$-45.87M
1W Leistung:
-0.88%
1M Leistung:
-3.46%
6M Leistung:
+39.47%
1J Leistung:
+205.14%
1-Tages-Spanne:
$84.50
$87.20
1-Wochen-Bereich:
$83.46
$87.20
52-Wochen-Spanne:
$27.80
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
84.56 | 12.02B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
522.64 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.89 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus
ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance
Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - BioSpace
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
Have Arrowhead Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR - TradingView
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares - Stock Titan
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares - Stock Titan
ARWR Looks 53.4% Overvalued on GF Value™ - GuruFocus
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Arrowhead Pharmaceuticals, Inc.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion - TipRanks
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan
Arrowhead Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | HDP1 | US04280A1007 - marketscreener.com
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Biotech Gem with 24.74% Upside - DirectorsTalk Interviews
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st
FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arrowhead Pharmaceuticals Inc.R (HDP1.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Arrowhead Pharmaceuticals, Inc.
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PERRY MICHAEL S | Director |
Aug 18 '26 |
Sale |
87.30 |
11,600 |
1,012,680 |
111,459 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):